Date: 2015-12-07
Type of information: Nomination
Compound:
Company: Immune Pharmaceuticals (USA - MA, Israel)
Therapeutic area: Cancer - Oncology - Immunological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 7, 2015, Immune Pharmaceuticals announced that it has appointed G. John Mohr as senior vice president of business development and a member of the Immune executive committee. In this role, John Mohr will be responsible for overseeing alliance and business development activities for the Company. John Mohr has served in the pharmaceutical business for over twenty years in multiple functions including business development, strategic planning and marketing. Prior to joining Immune, he was managing director at the consulting firm BioAsset Advisors advising public and private companies on strategic partnering and licensing activities. John Mohr previously served as senior vice president with CV Therapeutics, a publicly traded drug company focused on innovative cardiovascular therapeutics, and he lead several major global transactions with Menarini and Astellas. In addition, he was instrumental in the $1.4 billion sale of the company to Gilead in 2009. Prior to that, he was the chief operating officer for Topigen Pharmaceuticals, a clinical stage company developing innovative therapeutics in the respiratory field. He was senior vice president with Atherogenics and President of Fournier Pharma US, where he delivered billion dollar deals with AstraZeneca and Abbott. John is a graduate of Drexel University in Finance and Accounting, a CPA and certified licensing executive.
Financial terms:
Latest news:
